Dendritic Cell Vaccines and Immunotherapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 272
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue on dendritic cell vaccines and immunotherapy. Immunotherapy still needs to be perfected and dendritic cell (DC) vaccines have much to offer in this context. DC, drawing from their physiological role, are powerful tools for inducing, regulating, and directing the course of (therapeutic) immune responses. Our growing knowledge of their biology should allow us to exploit their potential to achieve better translational results. This issue aims to bring together original research articles and reviews on strategies that exploit the many activities of DC and their subtypes in therapeutic settings, either by enhancing ineffective responses or curbing pathogenic responses. Research areas may include (but are not limited to) the generation and therapeutic uses of DC subtypes, the characterization of immune responses induced by DC-vaccines, tolerogenic DC in transplants or autoimmunity, and the combination of DC-vaccines with other therapeutic approaches.
I look forward to receiving your contributions.
Prof. Dr. José A. Barbuto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dendritic cells
- cell-based therapy
- immunotherapy
- tumor antigens
- cancer vaccines
- cell-based vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
